EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles.
EVerZom has raised $11.6M in total funding. The most recent round was Series A. The last funding was announced in October 2025.
EVerZom's investors include Bpifrance, European Innovation Council, European Innovation Council Fund, Capital Cell, Capital Grand Est.
EVerZom is headquartered in Paris, France.
EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles.
EVerZom is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EVerZom — Funding & Investors." VCBacked, October 14, 2025, https://www.vcbacked.co/company/everzom. Accessed July 20, 2026.
VCBacked. (2025). EVerZom — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/everzom
{{cite web |title=EVerZom — Funding & Investors |url=https://www.vcbacked.co/company/everzom |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated